Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.11% to 5,842.91 and the Dow Jones Industrial Average DJIA rising 0.

Palantir stock rebounds, sales of Eli Lilly’s blockbuster GLP-1 medicines miss estimates, and Boeing’s 2024 deliveries fall sharply from a year earlier.

though drops for Eli Lilly and other influential stocks kept indexes in check. The Standard & Poor's 500 rose 0.1% as three out of every four stocks in the index climbed. The Dow Jones industrial average added 221 points, or 0.5%, and the Nasdaq composite ...

2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average ( ^DJI 0.78%) had just a 12.9% return, compared to 23.3% for the S&P 500 ( ^GSPC 1.00%) and 28.6% for the Nasdaq Composite.

Drops for Eli Lilly and other influential companies are weighing on U.S. indexes Tuesday, even though most of the market is rising following an encouraging update on inflation.

The Dow Jones Industrial Average rose on Tuesday as traders weighed ... they had for obesity drugs may not materialize as hoped. Lilly shares, which were approaching a trillion-dollar market ...

"Eli Lilly Cuts 4Q Sales Outlook After Sluggish Growth for Incretin Drugs," published at 10:06 a.m. ET, incorrectly said the outlook was around $400 below the low end of its last estimated range ...

The Danish drug company said an experimental weight-loss shot helped patients lose over one-fifth of their bodyweight. Novo's U.S. and [Europe-listed s

Eli Lilly ( LLY 2.45%) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose by more than 2% on the day, thanks largely to news from a rival. That performance was in contrast to the S&P 500 's ( ^GSPC -0.29%) trajectory; the closely watched index sank marginally by 0.3%.

Argus Research analyst Jasper Hellweg maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday. The company’s shares

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep correction. Lilly is by no means in bad shape, but because the stock's price has become so inflated in recent years, so have expectations.

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow